Iswarya Fertility Center Raises Rs 350 Crore From OrbiMed Asia in Major IVF Sector Deal

Chennai-based Iswarya Fertility Center has raised more than Rs 350 crore, roughly $37 million, from global healthcare investment firm OrbiMed Asia. The company has described the round as one of the largest growth investments seen in India’s IVF sector to date.

Iswarya currently runs a network of more than 85 centres spread across eight states, giving it one of the wider footprints among fertility care providers in the country. The fresh capital is earmarked for opening new centres in both existing and underserved markets, strengthening clinical infrastructure, and building out digital capabilities.

Managing director Arun Muthuvel said the company’s focus for its next phase is to ‘deepen our pan-India presence, enter underserved geographies and keep raising the bar on clinical outcomes,’ adding that investment would go into people, technology and patient experience. Part of the funding will also expand the company’s embryology talent pipeline.

Veda Corporate Advisors acted as financial adviser to Iswarya and its promoters on the transaction. VP Rajan, managing director at Veda Corporate Advisors, said the deal ‘drew strong interest from marquee investors,’ pointing to broader investor appetite for India’s fertility and reproductive healthcare space.

The investment lands at a time when IVF and fertility services are seeing rising demand across India’s smaller cities, not just metros, making the underserved-market expansion a central part of Iswarya’s growth plan going forward.